Trump Expected To Nominate Heidi Overton As FDA Commissioner, Ending A Leadership Gap

President Donald Trump has reportedly selected, or is expected to select, Heidi Overton to serve as the next commissioner of the FDA. The White House had not officially announced the nomination at publication, but both reports pointed to Overton, now deputy director of domestic policy for the White House, as the administration’s choice.

Overton arrives as a known figure inside the Trump administration rather than an outside regulator. She has led health policy from the start of Trump’s term, according to STAT, and has been visible at White House announcements on drug pricing, peptides, psychedelic therapies, and the executive order to split the measles, mumps and rubella vaccines into three separate shots. That proximity to the administration is part of the signal here: the FDA may be getting a commissioner whose mandate is to execute existing White House health priorities while trying to steady an agency whose review norms have become less predictable.

The Road Here

Overton would take over an agency that has lacked permanent leadership since former FDA commissioner Marty Makary left in May. The FDA has since been led in an acting capacity by Kyle Diamantas, who has moved to reverse some Makary-era policies, including rereviews tied to regulatory rejections for companies such as Replimune and Capricor Therapeutics, according to BioSpace.

Her background is more clinical and policy-focused than traditionally regulatory. BMO Capital Markets described her credentials as strong, citing a medical degree from the University of New Mexico, a general surgery residency at Johns Hopkins, and a PhD in clinical investigation from the Johns Hopkins Bloomberg School of Public Health. Before joining the White House, she served as chief policy officer and vice chair for the Center for a Healthy America at the America First Policy Institute. BioSpace also reported that she began working with Trump during the COVID response in 2019.

STAT described Overton as a powerful health policy voice in Trump’s second term who at times frustrated leaders of the Make America Healthy Again movement. It also said she helped oversee major administration efforts including redesigning the food pyramid, overhauling the childhood vaccine schedule, and working out pricing deals with pharmaceutical companies.

The Regulatory Picture

The commissioner’s job waiting for Overton is unusually defined by unfinished internal choices. BioSpace noted that many high-level leadership posts remain vacant and are being filled by acting officials, including the top role at the Center for Biologics Evaluation and Research. That matters because staffing decisions could shape whether controversial policies launched under Makary survive, are revised, or are quietly abandoned.

One immediate test is the “radical transparency” push associated with Department of Health and Human Services Secretary Robert F. Kennedy Jr. Under that effort, Makary implemented a policy to publish complete response letters detailing drug application rejections in real time. BMO called those disclosures helpful in understanding FDA decision-making, but BioSpace reported the policy has also drawn a citizen petition and other legal pushback. BMO said the biggest near-term signal for predictability will be whether Overton keeps, revises, or scraps the complete response letter policy.

Another unresolved issue is the Commissioner’s National Priority Vouchers, which BioSpace described as a controversial program granting regulatory fast passes to companies that meet some Trump administration priorities. Makary and former CBER chief Vinay Prasad also put in place the “plausible mechanism” framework for ultra-rare disease therapies, creating a path that allowed single-arm trials instead of randomized tests. BMO said the framework’s survival is untested now that both men are gone and CBER remains vacant, though it expects Overton to keep it alive because of support from advocates.

What Her Selection Signals

For industry, Overton’s selection does not by itself resolve the FDA’s core problem. BMO called the reported pick a “modest positive” because it removes a leadership overhang and places a credentialed physician in charge, but the firm said the more important question is whether she can restore credibility and predictability to the drug review process. Truist Securities took a similar view, describing the choice as on-brand for the administration: a physician-scientist already inside its orbit and already visible in regulatory policy rollouts.

That combination could cut two ways. BioSpace reported Truist’s view that Overton could drive healthy internal debate while ultimately ceding to the administration, which the firm said may be what investors want from the role. In practical terms, that suggests continuity on broad White House priorities but leaves open how much independence she would exercise on procedural questions that affect approval timelines, review standards, and sponsor confidence.

She would also inherit an agency strained by staffing losses. BioSpace said at least 3,000 staffers have left since the Trump administration took over, though the FDA has apparently hired an additional 600 employees and plans to onboard about 2,200 more. That makes the commissioner’s job partly operational: a permanent leader can change policy, but rebuilding confidence in review consistency also depends on whether the agency can stabilize the people and offices that carry those decisions out.

If Trump formally sends Overton’s nomination to the Senate and she is confirmed, drugmakers will get more than a new name at the top of the FDA. They will get an early read on whether this administration wants a more legible regulator, or simply a more aligned one.